Discovery of the first-in-class dual histone deacetylase–proteasome inhibitor
Dual-or multitarget drugs have emerged as a promising alternative to combination therapies.
Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) …
Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) …
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor
S Bhatia, V Krieger, M Groll, JD Osko… - Journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
Dual-or multitarget drugs have emerged as a promising alternative to combination therapies.
Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) …
Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) …
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor
S Bhatia, V Krieger, M Groll, JD Osko… - Journal of Medicinal …, 2018 - hero.epa.gov
Dual-or multitarget drugs have emerged as a promising alternative to combination therapies.
Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) …
Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) …
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
S Bhatia, V Krieger, M Groll, JD Osko… - Journal of Medicinal …, 2018 - europepmc.org
Dual-or multi-target drugs have emerged as a promising alternative to combination
therapies. Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase …
therapies. Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase …
[HTML][HTML] Discovery of the first-in-class dual histone deacetylase-proteasome inhibitor
S Bhatia, V Krieger, M Groll, JD Osko… - Journal of medicinal …, 2018 - ncbi.nlm.nih.gov
Dual-or multi-target drugs have emerged as a promising alternative to combination
therapies. Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase …
therapies. Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase …
[引用][C] Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor
S Bhatia, V Krieger, M Groll, J Osko, N Rebing… - Journal of Medicinal …, 2020 - osti.gov
Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell
death of chronic myeloid leukemia cells by an ROS-mediated mechanism and …
death of chronic myeloid leukemia cells by an ROS-mediated mechanism and …
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
S Bhatia, V Krieger, M Groll, JD Osko… - Journal of Medicinal …, 2018 - europepmc.org
Dual-or multi-target drugs have emerged as a promising alternative to combination
therapies. Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase …
therapies. Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase …